News and Events
Stem cell–derived natural killer cells engineered to attack solid tumors
Cancer-killing natural killer cells could pave the way to off-the-shelf immunotherapy for solid tumors.
Read More
Mary Kearney discusses coronavirus with National Geographic
Mary Kearney, Ph.D., Senior Scientist in the Host-Virus Interaction Branch, was recently quoted in a National Geographic article discussing how long coronavirus lasts inside the body. “Where there’s long-term persistence, there can be long-term consequences,” she says.
Read More
Clinical trial tests combination therapy for glioblastoma multiforme
Glioblastoma multiforme (GBM) is a type of brain cancer where treatments include radiation therapy, chemotherapy and surgery, but survival rates are poor. Investigators are testing an anticancer drug selinexor, which may make GBM cells less resistant to radiation therapy and allow radiation therapy to kill more cancer cells.
Read More
In Memoriam: Gilbert Howlett Smith, Ph.D.
The Center for Cancer Research mourns the recent death of colleague and friend Gilbert Howlett Smith, Ph.D. He was a valued and much liked member of the NCI community since 1965.
Read More
Sarcoma Awareness Month
To recognize Sarcoma Awareness Month this July, we are highlighting our researchers who are advancing research discovery in this field. Learn more...
Read More
Trial shows aggressive cancer treatment is appropriate for people with HIV-associated primary central nervous system lymphoma
New research from CCR scientists shows that chemoimmunotherapy with antiretroviral therapy can lead to long-lasting remissions of HIV-associated primary central nervous system lymphoma without compromising neurocognitive function.
Read More
Study finds drug beneficial for shrinking mesothelioma tumors
A drug that is designed to boost the immune system against mesothelioma, when combined with immunotherapy, was found to be beneficial in a small study involving ten patients. The results suggest that the drug LMB-100 could prolong the life of some patients with advanced disease.
Read More
Clinical trial studies combination therapy for certain mature T-cell cancers that have not responded to treatment
Adult T-cell leukemia/lymphoma (ATLL) and mycosis fungoides/Sézary syndrome (MF/SS) are fast-growing cancers that form in T cells, a type of white blood cell that is key to the body’s immune response. A clinical trial is being conducted at the NIH Clinical Center to test a combination therapy for these rare cancers.
Read More
Clinical trial tests targeted radioactive agent as therapy for metastatic prostate cancer
Prostate-specific membrane antigen (PSMA) is present on the surface of all prostate cancer cells but is highly expressed on cells of castration-resistant prostate cancer (mCRPC). Frank Lin, M.D., Investigator in the the Molecular Imaging Program, is leading NCI’s effort to study the effect of targeted treatment with a radioactive agent to test dosing and overall effect for these patients.
Read More
A Conversation with Christina Annunziata, M.D., Ph.D.
Christina Annunziata, M.D., Ph.D., is an Investigator in the Women’s Malignancies Branch at the Center for Cancer Research. She has spent most of her career studying the molecular underpinnings of ovarian cancer with the goal of discovering novel treatments. In our Q&A, Dr. Annunziata discusses her personal and professional milestones as well as new directions for her research.
Read More
New chemical sequencing reaction helps unravel the role of an ancient RNA modification
CCR researchers and collaborators have developed a novel chemical reaction that enables the quantitative mapping of an ancient and enigmatic RNA modification that is found in nearly all organisms on earth, providing fundamental insights that are potentially important for tumor biology and cancer treatment.
Read More